Floatz logo

Tegavivint

Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements

Lapo AlinariSmall moleculePhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

24 Active assets in the Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Yazeed Sawalha
Phase 2B
Cyclophosphamide
Mayo Clinic
Phase 2B
DEXAMETHASONE
National Cancer Institute (NCI)
Phase 2B
Ibrutinib
National Cancer Institute (NCI)
Phase 2B
Pembrolizumab
Mayo Clinic
Phase 2CCC

View all 28 →

Same molecule, other indications

Tegavivint is also rated in:

desmoid tumorDormant
CCC
Indicative ·
48 / 100
View asset →
endometrial carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
Ewing sarcomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →